Full-Time

Clinical Research Associate 2

Posted on 5/9/2026

Fortrea

Fortrea

10,001+ employees

Global CRO managing phase I–IV trials

No salary listed

Sydney NSW, Australia

Hybrid

Based in Sydney; hybrid role with 3 days in office; travel up to 60% to study sites.

Category
Biology & Biotech (1)
Requirements
  • University or college degree, or certification in a related allied health profession from an appropriately accredited institution (e.g., nursing licensure). An equivalent amount of experience can be substituted as appropriate.
  • Thorough understanding of ICH GCP Guidelines and understanding of local regulatory requirements.
  • Thorough knowledge of monitoring procedures.
  • Basic understanding of the clinical trial process.
  • Fluent in local office language and in English, both written and verbal.
  • Fortrea may consider relevant and equivalent experience in lieu of educational requirements.
  • Typically 2 years of onsite clinical site monitoring experience (Site Initiation Visit - SIV - Close out).
  • Ability to monitor study sites independently according to monitoring plan, project requirements, SOPs, and ICH GCP guidelines.
  • Ability to work with minimal supervision.
  • Understanding of Serious Adverse Event (SAE) reporting, process production of reports, narratives and follow up of SAEs.
  • Good planning, organization, and problem-solving abilities.
  • Works efficiently and effectively in a matrix environment.
Responsibilities
  • Site management responsibility for clinical studies according to Fortrea’s Standard Operating Procedures, ICH GCP Guidelines, applicable project plans and Sponsor requirements, including verification of study training records.
  • Conducts site monitoring responsibilities for clinical trials according to Fortrea’s Standard Operating Procedures (SOPs), ICH guidelines and GCP; including Pre-study, Site Initiation, Process Monitoring, Routine Monitoring, and Close-out Visits.
  • Prepares and implements project plans related to Clinical Monitoring responsibilities.
  • Ensures the protection of subjects by verifying that informed consent procedures and protocol requirements are adhered to alongside applicable regulatory requirements.
  • Safeguards data integrity by careful source document review, source document verification, query generation, and resolution against established data review guidelines on Fortrea or client data management systems.
  • Confirms Site Regulatory documents and applicable eTMF/Sponsor Documents are complete and current throughout the duration of the trial.
  • Guarantees that the study Investigational Product inventory and accountability is accurate and that study materials are stored securely and per protocol requirements.
  • Ensures adherence to global quality control and CRA performance metrics.
  • Ensures audit readiness at site level.
  • Acts in the project role of a Lead CRA as assigned.
  • General On-Site Monitoring Responsibilities:
  • Ensure the study staff who will conduct the protocol have received the proper materials and instructions to safely enter subjects/patients into the study. Ensure the protection of study subjects or patients by performing eligibility review, verifying that screening, informed consent procedures and protocol requirements are adhered to according to the applicable regulatory requirements.
  • Ensure the integrity of the source data reported by careful source document review. Monitor data for missing or implausible data.
  • Ensure study data completeness, accuracy, consistency, and compliance; identify deficiencies, deviations and discrepancies, and initiate corrective action as required.
  • Ensure the resources of the Sponsor and Fortrea are spent wisely by performing the required monitoring tasks in an efficient manner, according to SOPs and established guidelines, including managing travel expenses in an economical fashion according to Fortrea travel policy.
  • Travel, including air travel, may be required and is an essential function of the job.
  • Prepare and submit accurate and timely trip reports.
  • Independently perform eCRF review, 100% source data verification, query generation and resolution against established data review guideline with or without direct supervision, on Fortrea or client data management systems, as assigned by management.
  • Assist with the administration of clinical research projects, recruiting investigators (if applicable), collecting investigator documentation and site management.
  • Update, navigate, and maintain Fortrea or study/Sponsor-specific trial management tools/eClinical systems.
  • Track IP shipments and supplies, as needed.
  • Track and follow-up on serious adverse events as assigned.
  • Work closely with the study team, align monitoring to critical study timelines ensuring study deliverables are met.
  • Prepare and implement study-specific monitoring plans and site Initiation slides, as assigned.
  • Attend investigators’ meetings (if applicable), project team meetings and teleconferences, and others as needed.
  • Present training content for site initiation.
  • Assist with training of new employees (e.g., co-monitoring).
  • All other duties as needed or assigned.

Fortrea is a global contract research organization (CRO) that provides clinical trial management, clinical pharmacology services, and consulting for pharmaceutical, biotechnology, and medical device companies. It runs Phase I–IV trials, operates its own clinical trial sites, and handles patient recruitment including healthy volunteers and patients with specific conditions. It offers mobile clinical solutions to improve patient retention and adherence and tailors its services to each client’s needs, generating revenue from fees for research and development services. Fortrea aims to streamline the clinical trial process and support innovation in its clients' trials by delivering customized, end-to-end trial delivery solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • FIT platform expansion across clinical pharmacology, development, and medical devices drives revenue.
  • Strong biotech activity and three consecutive quarters above 1.1x book-to-bill sustains growth.
  • Over $0.5 billion liquidity enables strategic investments and debt reduction initiatives.

What critics are saying

  • IQVIA's superior AI platform erodes Fortrea's biotech bookings within 12-18 months.
  • Customer concentration exposes Fortrea to 15-20% revenue loss from single contract.
  • PPD and ICON undercut Fortrea's functional services pricing, compressing margins significantly.

What makes Fortrea unique

  • Fortrea Intelligent Technology suite automates clinical trial workflows with AI-powered analytics.
  • Book-to-bill ratio of 1.15x in Q1 2026 signals strong biotech demand momentum.
  • Adjusted EBITDA surged 55% year-over-year to $47 million through operational efficiency.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Fortrea who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Vacation

Company News

Connectweb Technologies, Inc.
Apr 7th, 2026
Fortrea unveils Fortrea Intelligent Technology(TM) to help sponsors and sites run Smarter, more integrated trials.

Fortrea unveils Fortrea Intelligent Technology(TM) to help sponsors and sites run Smarter, more integrated trials. Fortrea Holdings Inc AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality. Highlights: * Designed to transform clinical trial operations for sponsors, sites and study teams * Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality * Builds on Fortrea's flagship platform Xcellerate(R) to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology(TM)(FIT), a suite of innovative technology solutions designed to transform clinical trial operations. By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality. An Innovative, Intelligent Suite of Clinical Solutions FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate(R) platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem. The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS). FIT solutions are arranged into three pillars: * Lifecycle: Deliver Trials Faster with Confidence Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF. * Foresight: Turn Data into Actionable Insights Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight. * Companion: Empowering Study Teams to Work Smarter Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration. "We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus," said Chief Information Officer Alejandro Martinez Galindo. "Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk." Xcellerate(R) Anchors the Intelligent Suite Xcellerate(R), Fortrea's platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering. Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate(R) can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research. "We expect these Xcellerate(R) enhancements and the broader FIT platform will be game changers for our study teams and our clients," said Chief Operating Officer and President, Clinical Development Mark Morais. "Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us - all of which can make the difference in getting life-changing treatments to patients faster and more efficiently." Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Connectweb partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Connectweb on LinkedIn, X and Bluesky. Fortrea Contacts: Jennifer Minx (Media) - 919-410-4195, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] Tracy Krumme (Investors) - 984-385-6707, [email protected]

Yahoo Finance
Apr 7th, 2026
Fortrea launches AI-powered technology suite to speed up clinical trials

Fortrea, a global clinical research organisation, has unveiled Fortrea Intelligent Technology (FIT), an AI-enhanced suite of solutions designed to transform clinical trial operations for sponsors, sites and study teams. The platform builds on Fortrea's Xcellerate system to deliver persona-driven, AI-powered solutions that automate workflows and streamline oversight. FIT is organised into three pillars: Lifecycle, which accelerates trials from pre-award to final eTMF; Foresight, providing near-real-time insights and risk mitigation through intuitive dashboards; and Companion, offering AI-powered tools to boost productivity and collaboration. The suite is available for clinical pharmacology, clinical development and medical device development, deployable in full service and functional service models, with select components available as software-as-a-service.

Yahoo Finance
Feb 26th, 2026
Fortrea reports $2.7B revenue, $190M EBITDA as book-to-bill hits 1.14x

Fortrea reported Q4 revenue of $660.5 million, down 5.2% year-over-year, and full-year revenue of $2.723 billion, up 1% and within guidance. Q4 adjusted EBITDA was $54 million, whilst full-year adjusted EBITDA reached $189.9 million. The company posted a Q4 GAAP net loss of $32.5 million. Management noted improving demand, with Q4 book-to-bill at 1.14x and backlog at $7.7 billion, driven by higher client engagement and increased biotech RFP flow. Fortrea exceeded cost-savings targets, delivering $153 million gross savings, and generated strong Q4 operating cash flow of $129.1 million. The company repurchased $75.7 million of senior notes and ended with over $600 million liquidity. For 2026, Fortrea guided revenue of $2.55–2.65 billion with adjusted EBITDA of $190–220 million.

Yahoo Finance
Feb 25th, 2026
Fortrea reports Q4 results tomorrow with revenue expected to decline 4.3% year on year

Clinical research company Fortrea Holdings reports Q4 earnings tomorrow. Analysts expect revenues to decline 4.3% year on year, following a 1.8% decrease in the same quarter last year. Last quarter, Fortrea beat revenue expectations with $701.3 million, up 3.9% year on year, and issued full-year guidance exceeding analysts' forecasts. However, the company has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have largely maintained their estimates over the last 30 days. Shares have declined 36.8% over the past month, underperforming the drug development inputs and services segment, which averaged a 1.1% decline. The stock currently trades at $10.98 against an average analyst price target of $16.44.

The Associated Press
Feb 17th, 2026
Fortrea appoints Oren Cohen as chief medical officer and Scott Dove as president of Clinical Pharmacology Services

Fortrea, a global contract research organisation, has expanded its executive team with two appointments. Oren Cohen, who previously served as both chief medical officer and president of Clinical Pharmacology Services, will now focus solely on his CMO responsibilities, overseeing medical strategy, scientific leadership and governance across Fortrea's portfolio. Scott Dove has joined as president of Clinical Pharmacology Services, responsible for early clinical development solutions across Fortrea's global network. Dove brings over 25 years of drug development experience, most recently serving as chief operating officer at Aravive and holding leadership roles at PPD, Allergan and Furiex Pharmaceuticals. Both Cohen and Dove serve on Fortrea's Executive Committee. The company provides clinical trial management and consulting services across more than 20 therapeutic areas.